{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:44:24Z","timestamp":1772192664421,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.carrev.2006.07.002","type":"journal-article","created":{"date-parts":[[2006,12,15]],"date-time":"2006-12-15T07:27:38Z","timestamp":1166167658000},"page":"234-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure"],"prefix":"10.1016","volume":"7","author":[{"given":"Andrew E.","family":"Ajani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2006.07.002_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.CIR.0000109691.16944.DA","article-title":"Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE)","volume":"109","author":"Steg","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.carrev.2006.07.002_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1067\/mhj.2003.53","article-title":"Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials","volume":"145","author":"Hasdai","year":"2003","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.carrev.2006.07.002_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.carrev.2006.07.002_bib4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.carrev.2006.07.002_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.carrev.2006.07.002_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0895-7061(99)00042-4","article-title":"Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation","volume":"12","author":"Borghi","year":"1999","journal-title":"Am J Hypertens"},{"issue":"9266","key":"10.1016\/j.carrev.2006.07.002_bib7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.carrev.2006.07.002_bib8","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.carrev.2006.07.002_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"issue":"9223","key":"10.1016\/j.carrev.2006.07.002_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)02427-2","article-title":"Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease","volume":"356","author":"Wallentin","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.carrev.2006.07.002_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838906001850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838906001850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:04:36Z","timestamp":1761559476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838906001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S1553838906001850"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2006.07.002","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2006.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}